Plasma miR-22-5p, miR-132-5p, and miR-150-3p Are Associated with Acute Myocardial Infarction

• Published in: BioMed research international Vol. 2019; no. 2019; pp. 1 - 13
• Main Authors: Li, Feixing, Wang, Xiaoyuan, Yuan, Guili, Li, Fangjiang, Zhang, Pengxiang, Li, Huixian, Zhang, Aiai
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2019; Hindawi; Hindawi Limited
• Subjects: Angiogenesis; Bioindicators; Biomarkers; Body mass index; Calcium-binding protein; Cardiomyocytes; Cardiovascular disease; Cardiovascular diseases; Coronary artery disease; Diabetes; Diagnostic systems; Enzyme-linked immunosorbent assay; Gene expression; Genetics; Heart attacks; Heart diseases; Heparin; Hypertension; Kinases; Low level; MicroRNAs; miRNA; Myocardial infarction; Plasma levels; Ribonucleic acid; RNA; Troponin; Troponin I
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2019/5012648

Circulating microRNAs (miRNAs) are potential biomarkers for cardiovascular diseases. Our study aimed to determine whether miR-22-5p, miR-132-5p, and miR-150-3p represent novel biomarkers for acute myocardial infarction (AMI). Plasma samples were isolated from 35 AMI patients and 55 matched controls. Total RNA was extracted, and quantitative real-time PCR and ELISA were performed to investigate the expressions of miRNAs and cardiac troponin I (cTnI), respectively. We found that plasma levels of miR-22-5p and miR-150-3p were significantly higher during the early stage of AMI and their expression levels peaked earlier than cTnI. Conversely, circulating miR-132-5p was sustained at a low level during the early phase of AMI. All three circulating miRNAs were correlated with plasma cTnI levels. A receiver operating characteristic (ROC) analysis suggested that each single miRNA had considerable diagnostic efficacy for AMI. Moreover, combining the three miRNAs improved their diagnostic efficacy. Furthermore, neither heparin nor medications for coronary heart disease (CHD) affected plasma levels of miR-22-5p and miR-132-5p, but circulating miR-150-3p was downregulated by medications for CHD. We concluded that plasma miR-22-5p, miR-132-5p, and miR-150-3p may serve as candidate diagnostic biomarkers for early diagnosis of AMI. Moreover, a panel consisting of these three miRNAs may achieve a higher diagnostic value.